Journal of Clinical Oncology, Vol 23, No 14 (May 10), 2005: pp. 3270-3278
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.11.478
Adjuvant Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer
Katherine M.W. Pisters,
Thierry Le Chevalier
From the University of Texas M. D. Anderson Cancer Center, Houston, TX; and Institut Gustave Roussy, Villejuif, France
Address reprint requests to Katherine M.W. Pisters, MD, UT M. D. Anderson Cancer Center, Unit 432, PO Box 301402, Houston, TX 77230-1402; e-mail: kpisters{at}mdanderson.org.
Surgery alone has long been the standard treatment for patients with operable non–small-cell lung cancer (NSCLC). However, despite complete resection, 5-year survival rates have been disappointing, with about 50% of patients eventually suffering relapse and death from disease. Randomized trials conducted in the 1980s hinted at a survival benefit for postoperative cisplatin-based regimens, but they were underpowered. A meta-analysis published in 1995 found a nonsignificant 13% reduction in the risk of death associated with cisplatin-based chemotherapy, with an increase of survival of 5% at 5 years. This led to renewed interest in adjuvant chemotherapy in resected NSCLC. Thousands of patients have been included in a new generation of randomized trials in the last 10 years. Most of these recent studies have now been reported and several have demonstrated a clear survival advantage for patients treated with platin-based adjuvant therapy. These results also suggest a greater benefit with modern two-drug regimens. In view of the most recent data, postoperative platin-based chemotherapy can now be considered the standard of care for completely resected NSCLC patients with good performance status.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:
|
|
|
|
 
W. J. Scott, J. Howington, S. Feigenberg, B. Movsas, and K. Pisters
Treatment of Non-small Cell Lung Cancer Stage I and Stage II: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest,
September 1, 2007;
132(3_suppl):
234S - 242S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yanagisawa, S. Tomida, Y. Shimada, Y. Yatabe, T. Mitsudomi, and T. Takahashi
A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non-Small-Cell Lung Cancer
J Natl Cancer Inst,
June 6, 2007;
99(11):
858 - 867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kobayashi, H. Kubo, T. Suzuki, K. Ishizawa, M. Yamada, M. He, Y. Yamamoto, H. Yamamoto, H. Sasano, H. Sasaki, et al.
Endogenous Secretory Receptor for Advanced Glycation End Products in Non-Small Cell Lung Carcinoma
Am. J. Respir. Crit. Care Med.,
January 15, 2007;
175(2):
184 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Inoue, M. Minami, H. Shiono, N. Sawabata, K. Ideguchi, and M. Okumura
Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: Pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement
J. Thorac. Cardiovasc. Surg.,
May 1, 2006;
131(5):
988 - 993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hishida, K. Nagai, J. Yoshida, M. Nishimura, G.-i. Ishii, M. Iwasaki, and Y. Nishiwaki
Is surgical resection indicated for a solitary non-small cell lung cancer recurrence?
J. Thorac. Cardiovasc. Surg.,
April 1, 2006;
131(4):
838 - 842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Belvedere and F. Grossi
Lung Cancer Highlights from ASCO 2005
Oncologist,
January 1, 2006;
11(1):
39 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bria, D. Giannarelli, E. Terzoli, T. L. Winton, K. Ding, and L. Seymour
Treatment of Resected Non-Small-Cell Lung Cancer
N. Engl. J. Med.,
October 6, 2005;
353(14):
1523 - 1524.
[Full Text]
[PDF]
|
|
|
|
